Overview

Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with low grade gliomas that has come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low grade gliomas compared to trametinib or everolimus alone.

Phase:

Phase 1

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Novartis Pharmaceuticals
Pediatric Brain Tumor Foundation
The Lilabean Foundation for Pediatric Brain Cancer Research

Treatments:

Everolimus
Trametinib